Concepedia

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei,

The Lancet HIV · 2019 · 165 citations · 12 references

DOI

Concepts

References

12

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Huldrych F. Günthard, Michael S. Saag, Constance A. Benson et al. · JAMA · 2016 · 656 citations · Full text

, , +17

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 380 citations

, , +15

2015 update of the drug resistance mutations in HIV-1

Annemarie M. J. Wensing, Vincent Cálvez, Robert W. Shafer et al. · PubMed · 2015 · 361 citations · Full text

, , +16

Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens

Jamison Norwood, Megan Turner, Carmen Bofill et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2017 · 282 citations

, , +13

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

Christian Hoffmann, Tanya Welz, Michael Sabranski et al. · HIV Medicine · 2016 · 281 citations · Full text

, , +17